The FDA is Taking a Big Risk on AI
CareTalk: Healthcare. Unfiltered.
00:00
Evaluating the Risks of Rapid AI Implementation in Drug Review Processes
This chapter examines the FDA's initiative to adopt AI-assisted reviews for new therapies, highlighting both the positive feedback from pilot programs and the potential dangers of rushing into full implementation. It also addresses concerns about the agency's loss of young talent, which may impact its future ability to innovate and uphold safety standards.
Transcript
Play full episode
